BVXV - Biondvax Pharmaceuticals reports Q2 results

2023-08-11 11:01:11 ET

• Biondvax Pharmaceuticals press release ( NASDAQ: BVXV ): Q2 Financial (loss) income for the three months ended June 30, 2023, amounted to $1.16 million loss compared with $0.28 million income for the three months ended June 30, 2022.
• Net loss for the three months ended June 30, 2023, amounted to $3.76 million compared with $2.98 million for the three months ended June 30, 2022.
• As of June 30, 2023, BiondVax had cash and cash equivalents of $7.6 million as compared to $14.2 million as of December 31, 2022.

For further details see: